Outlook Therapeutics (OTLK) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Outlook Therapeutics (OTLK) has outperformed Tiziana Life Sciences (TLSA) over the past year, losing 49.6% versus a loss of 50.7%. Over five years, TLSA leads with a -25.2% price change compared with -98.6% for OTLK. Tiziana Life Sciences is the larger company by market cap ($143.8 million vs $137.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OTLK | TLSA |
|---|---|---|
| Share price | $0.564 | $1.13 |
| Market cap | $137.30M | $143.80M |
| 1-day change | -4.41% | +2.73% |
| YTD return | -62.66% | -24.16% |
| 1-year return | -49.57% | -50.66% |
| 5-year return | -98.60% | -25.17% |
| EPS (TTM) | $-0.70 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.54 | $2.30 |
| 52-week low | $0.161 | $0.76 |
| Distance from 52-week high | -77.78% | -50.87% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +791.84% | +606.19% |
| Average volume | 13.43M | 717.23K |
| Shares outstanding | 243.45M | 127.26M |
| Employees | 17 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
OTLK vs TLSA FAQ
Which is bigger, Outlook Therapeutics or Tiziana Life Sciences?
Tiziana Life Sciences (TLSA) is larger, with a market capitalization of $143.80M compared with $137.30M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, OTLK or TLSA?
OTLK returned -49.57% over the past 12 months, compared with -50.66% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are Outlook Therapeutics and Tiziana Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Outlook Therapeutics and Biotechnology: Pharmaceutical Preparations for Tiziana Life Sciences.